Skip to content
Shuttingdown

Kezar Life Sciences, Inc.

Pharmaceutical Preparations · SOUTH SAN FRANCISCO · CA

Distress signal

Moderate confidence (50%)

Updated Oct 8, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Kezar Life Sciences, Inc. deregistered its securities (May 21, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Kezar Life Sciences, Inc. deregistered its securities

    May 21, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 ef20072567_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-38543 Commission File Number KEZAR LIFE SCIENCES, INC. (Exact name of registrant as speci ed in its charter) 4000 Shoreline Court, Suite 300 South San Francisco, CA 94080 (650) 822-5600 (Address, including zip code, and telephone number, including area code,…”

  2. Kezar Life Sciences, Inc. was delisted from its exchange

    May 11, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001645666 Kezar Life Sciences, Inc. 001-38542 4000 Shoreline Court, Suite 300 South San Francisco CA CALIFORNIA 94080 (650) 822-5612 common stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-05-11”

  3. Kezar Life Sciences, Inc. received a delisting notice from its exchange

    May 8, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01. In connection with the consummation of the Offer and the Merger, the Company (i) notified The Nasdaq Stock Market LLC ( Nasdaq ) of the consummation of the Merger and (ii) requested that Nasdaq (A) suspend trading of the Shares effective before the opening of trading on May 11, 2026 and (B) file with the SEC a Notification of Removal from Listing and/or…”

Company information

Founded
—
Employees (estimate)
—
Industry
Pharmaceutical Preparations
Subindustry
—
Listing
SEC lists the ticker KZR on Nasdaq.
SEC CIK
0001645666
Website
—
LinkedIn
—
Headquarters
SOUTH SAN FRANCISCO, CA
Also known as
—
Legal entities
Kezar Life Sciences, Inc.

Sources

Every material source used to build this profile.

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Kezar Life Sciences, Inc. — Pharmaceutical Preparations (SIC 2834) — SOUTH SAN FRANCISCO, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 ef20072567_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-38543 Commission File Number KEZAR LIFE SCIENCES, INC. (Exact name of registrant as speci ed in its charter) 4000 Shoreline Court, Suite 300 South San Francisco, CA 94080 (650) 822-5600 (Address, including zip code, and telephone number, including area code,…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001645666 Kezar Life Sciences, Inc. 001-38542 4000 Shoreline Court, Suite 300 South San Francisco CA CALIFORNIA 94080 (650) 822-5612 common stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-05-11
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01. In connection with the consummation of the Offer and the Merger, the Company (i) notified The Nasdaq Stock Market LLC ( Nasdaq ) of the consummation of the Merger and (ii) requested that Nasdaq (A) suspend trading of the Shares effective before the opening of trading on May 11, 2026 and (B) file with the SEC a Notification of Removal from Listing and/or…
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:32 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:11 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:34 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 12, 2026, 12:04 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 11, 2026, 12:02 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:39 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.